James Quigley
Stock Analyst at Morgan Stanley
(1.49)
# 2,337
Out of 4,479 analysts
22
Total ratings
50%
Success rate
13.68%
Average return
Main Sectors:
5 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MOR MorphoSys AG | Downgrades: Equal-Weight | n/a | $18.10 | - | 5 | Jan 19, 2024 | |
| GRFS Grifols | Maintains: Neutral | $10 → $11 | $6.52 | +61.04% | 1 | Dec 5, 2023 | |
| KYMR Kymera Therapeutics | Maintains: Equal-Weight | $37 → $24 | $30.22 | -20.58% | 3 | Nov 13, 2023 | |
| GLPG Galapagos NV | Maintains: Equal-Weight | $42 → $40 | $25.34 | +57.85% | 10 | Aug 7, 2023 | |
| EVO Evotec SE | Upgrades: Overweight | $12 → $16 | $4.95 | +223.23% | 3 | Jun 23, 2023 |
MorphoSys AG
Jan 19, 2024
Downgrades: Equal-Weight
Price Target: n/a
Current: $18.10
Upside: -
Grifols
Dec 5, 2023
Maintains: Neutral
Price Target: $10 → $11
Current: $6.52
Upside: +61.04%
Kymera Therapeutics
Nov 13, 2023
Maintains: Equal-Weight
Price Target: $37 → $24
Current: $30.22
Upside: -20.58%
Galapagos NV
Aug 7, 2023
Maintains: Equal-Weight
Price Target: $42 → $40
Current: $25.34
Upside: +57.85%
Evotec SE
Jun 23, 2023
Upgrades: Overweight
Price Target: $12 → $16
Current: $4.95
Upside: +223.23%